Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

C’était l’histoire dont tout le monde parlait. En 2024, Novo Nordisk, grâce à ses traitements révolutionnaires contre l’obésité, s’imposait comme la première capitalisation boursière d’Europe, ...

More than one in four U.S. adults with diabetes used one of the injectable medicines that target the GLP-1 protein last year, ...

Eli Lilly has rolled out a prefilled pen version of its weight-loss drug Mounjaro at the same price as vials, aiming to ...

The Q2 pharma earnings season featured changes in the obesity race as well as insights into drugmakers’ views on tariffs and drug pricing.

Doctors report insurance cuts are forcing many U.S. patients on Wegovy and Zepbound to pay high out-of-pocket costs.

Lilly's Kwikpen debut intensifies rivalry with Novo Nordisk's Wegovy in the world's most populous diabetes market ...

Biogen CEO Chris Viehbacher says Novo Nordisk's Alzheimer's trial success could lead to combination therapies, boosting ...

Anna Sokolidou believes Tesla’s stock should trade at a fraction of its current price, citing fundamental weaknesses and ...

NVO stock climbs nearly 6% in August as Lilly's oral obesity candidate setback pivots investor sentiment toward the former's ...

Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

Novo Nordisk's growth in diabetes and obesity care makes it a strong buy. Click here for a full investment analysis of NVO ...